Lung Cancer Therapeutics Market Analysis 2026

Market Dynamics of the Lung Cancer Therapeutics

Key Drivers of the Lung Cancer Therapeutics

• The strong prevalence of lung cancer is notably driving market growth.

One of the most prevalent forms of cancer is lung cancer. Several reasons, including the aging population and lifestyle changes, have contributed to a notable increase in the number of new instances of cancer, particularly lung cancer, in recent years. In the United States, 6.2% of the population is at risk of developing lung cancer. Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals.
•    For instance, according to the 2022 report by the American Lung Association, while the disease remains the leading cause of cancer deaths among women and men, the survival rate over the past five years has increased from 21% nationally to 25% yet remains significantly lower among communities of color at 20%. Hence, the increasing prevalence of cancer and the need for effective treatment is likely to contribute to market growth.
(Source:https://www.lung.org/research/state-of-lung-cancer/key-findings)

• Rising pollution due to rapid industrialization increases the incidences of lung cancer

Air pollution (outdoor and indoor particulate matter and ozone) is closely linked to the rising prevalence of heart disease and strokes, lung cancer, lower respiratory infections, diabetes, and chronic obstructive pulmonary disease (COPD). The Global Burden of Disease Study Report (2019) ranks air pollution as the third leading cause of death worldwide. Globally, air pollution is responsible for 6.82 million deaths annually, of which 33% are caused by interior pollution and 66% by outdoor pollution. 
•    For instance, According to the conference organized by the Associated Chambers of Commerce and Industry of India (ASSOCHAM), ‘Lung Cancer- Awareness, Prevention, Challenges & Treatment’, air pollution is the leading cause of the rise of lung cancer in the country. Around 63 out of the 100 most polluted places on earth belong to India.
(Source:https://www.assocham.org/press-release-page.php?release-name=air-pollution-is-the-major-cause-of-lung-cancer-in-india-say-health-experts)

Restraints of the Lung Cancer Therapeutics

• Regional disparities in treatment will hamper the market for lung cancer therapeutics

Lung cancer is the most prevalent cause of cancer-related deaths globally, and its impact is particularly felt in lower- and middle-income countries (LMICs), where access to early and effective diagnosis and treatment is often restricted. WHO data show that whereas 90% of cancer patients in high-income countries have access to therapy, only roughly 30% of cancer patients in low-income countries do. There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Furthermore, the high maintenance cost of the instruments adds up to the total cost. By 2050, about two-thirds of all people over 60 will live in low- and middle-income countries.
•    For instance, The total cost of cancer to the global economy will reach 25.2 trillion international dollars between 2020 and 2050, according to an analysis of 29 cancers across 204 countries. Of that, five types of cancer will account for roughly half of that cost, including lung cancer.
(Source:https://www.advisory.com/daily-briefing/2023/03/09/cancer-costs)

How Did COVID-19 Impact The Lung Cancer Therapeutics Market

The COVID-19 pandemic still poses a threat to the world, particularly to those who already have lung illnesses. Lung cancer patients have faced numerous challenges as a result of the pandemic. About 95 out of 161 patients at the Fifth Affiliated Hospital of Sun Yat-sen University had postponed their return visit by April 2020, and 47 cases were ultimately identified as having delayed entry during the pandemic and needing to stop or postpone their normal anticancer therapy. As COVID-19 targets patients with advanced lung cancer, hospitals figure out how to be extremely meticulous. However, due to the declining number of COVID-19 instances, patients with lung cancer may expect their therapy approach to expand.  Many cancer patients have experienced changes in their lung cancer treatment plans.  COVID-19 reduced the number of lung cancer patients receiving cancer treatment.
•    For instance, a New study published by npj vaccines, shows bivalent COVID-19 booster increases antibody response in lung cancer patients, BA.5 bivalent booster dose enhanced neutralization of Omicron XBB (sub)variants in non-small cell lung cancer (NSCLC) patients.
(Source:https://www.news-medical.net/news/20231123/New-study-shows-bivalent-COVID-19-booster-increases-antibody-response-in-lung-cancer-patients.aspx)

Opportunities of the Lung Cancer Therapeutics

• The arrival of nanomedicine to treat lung cancer

According to research, inhalation chemotherapy based on nanotechnology is more effective than traditional chemotherapy and has fewer adverse effects. For the inhalation treatment of lung cancer, a wide range of nanocarriers have been studied, including liposomes, micelles, polymeric NPs, inorganic NPs, and solid lipid NPs. Smart nanoparticles and a unique surgical method are used in a recently disclosed, efficacious, and promising lung cancer therapeutic strategy that targets lung tumors (Advanced Therapeutics). The previous systems and therapies had certain technological limitations. The advanced lung cancer therapeutics instruments and systems help in removing the cancer cells effectively.
•    For instance, The Tata Institute in Mumbai has developed a tablet that could prevent cancer from recurring and reduce the side effects of treatment by 50%. The tablet, which will cost just ?100, is awaiting approval from the Food Safety and Standards Authority of India (FSSAI) and could be available in the market by June 2024.

(Source:https://economictimes.indiatimes.com/news/science/tata-institute-claims-new-breakthrough-cancer-treatment-only-costs-rs-100-heres-what-they-said/articleshow/108058030.cms?from=mdr)

Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. Market dominance is a result of consumers' growing propensity to buy pharmaceuticals from hospital pharmacies due to the availability of a large variety of medicines. Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals.

Frequently Asked Questions